- Global Pharma News & Resources

Oncology-Based In-vivo CRO Market is likely to US$ 2.9 by the end of 2033

In 2021, the global Oncology-based In-vivo CRO Market was estimated to be worth around $1 billion. With a projected CAGR of 10.9% over the next ten years, the market is expected to be worth nearly US$ 2.9 billion by the end of 2033. By 2033, the absolute dollar opportunity in the Oncology-based In-vivo CRO Market is expected to be US$ 1.8 billion.

According to Future Market Insights, the Oncology-based in-vivo CRO market grew at an 8.9% CAGR from 2018 to 2022 and is expected to grow at a 10.9% CAGR from 2023 to 2033.

To get more insights, Download Sample Copy @

Crucial information and forecast statistics covered in the Oncology-Based In-vivo CRO market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Oncology-Based In-vivo CRO Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Oncology-Based In-vivo CRO market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Oncology-Based In-vivo CRO market.

Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Oncology-Based In-vivo CRO market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Why Choose Future Market Insights

  • Serving domestic and international clients 24/7
  • Prompt and efficient customer service
  • Data collected from reliable primary and secondary sources
  • Highly trained and experienced team of research analysts
  • Seamless delivery of tailor-made market research reports

Discounted prices for new customers! Offer expires soon!

Ask an Analyst @

Oncology-Based In-vivo CRO Market: Segmentation

Valuable information covered in the FMI’s Oncology-Based In-vivo CRO market report has been segregated into key segments and sub-segments.

By Indication:

  • Blood Cancer
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Solid Tumors
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Other Indications
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft

Oncology-Based In-vivo CRO Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Oncology-Based In-vivo CRO market. Competitive information detailed in the Oncology-Based In-vivo CRO market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Oncology-Based In-vivo CRO market report.

Key players covered in the report include:

Jackson Laboratory, EVOTEC, WuXi AppTec, Toxicon Inc., Crown Bioscience, Taconic Biosciences, Eurofins Scientific, ICON Plc, Charles River Laboratory, and Covance

Important Questions Answered in the Oncology-Based In-vivo CRO Market Report

  • Which end user remains the top revenue contributor in different regional markets?
  • At what rate has the global Oncology-Based In-vivo CRO market been expanding during the forecast period?
  • How will the global Oncology-Based In-vivo CRO market look like by the end of the forecast period?
  • What innovative strategies are adopted by Oncology-Based In-vivo CRO market players to stay ahead of the pack?
  • What are the restraints affecting the growth of the global Oncology-Based In-vivo CRO market?

Buy Now @

Key Offerings of the Report

  • Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
  • Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
  • Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
  • Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with necessary information to take critical decisions
  • Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Oncology-Based In-vivo CRO market

About Us

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
United Arab Emirates
For Sales

Editor Details

Last Updated: 20-Mar-2023